TGF-β receptor signaling

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1333, Issue 2, 1997, Pages

  Derynck, Rik ^a   Feng, Xin Hua ^a  

^a Depts of Growth and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR SUBTYPE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CAENORHABDITIS ELEGANS; CANCER INHIBITION; CELL GROWTH; DROSOPHILA; ENZYME ACTIVITY; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; ANTIGENS, CD; CELL DIVISION; DNA-BINDING PROTEINS; DROSOPHILA; DROSOPHILA PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHOTRANSFERASES; PROTEOGLYCANS; RECEPTORS, CELL SURFACE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE-1;

CAENORHABDITIS ELEGANS;

EID: 0030702810     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-419X(97)00017-6     Document Type: Review

References (286)

1. Schlessinger J., Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron. 9:1992;383-391.
2. Kishimoto T., Taga T., Akira S. Cytokine signal transduction. Cell. 76:1994;253-288.
3. Heldin C.-H. Dimerization of cell surface receptors in signal transduction. Cell. 80:1995;213-223.
4. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 80:1995;225-236.
5. Karin M., Hunter T. Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr. Biol. 5:1995;747-757.
6. Pawson T. Protein modules and signalling networks. Nature. 373:1995;573-580.
7. Ihle J. Cytokine receptor signaling. Nature. 377:1996;591-594.
8. Moses H.L., Branum E.L., Proper J.A., Robinson R.A. Transforming growth factor production by chemically transformed cells. Cancer Res. 41:1981;2842-2848.
9. Roberts A.B., Anzano M.A., Lamb L.C., Smith J.M., Sporn M.B. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc. Natl. Acad. Sci. (USA). 78:1981;5339-5343.
10. Childs C.B., Proper J.A., Tucker R.F., Moses H.L. Serum contains a platelet-derived transforming growth factor. Proc. Natl. Acad. Sci. USA. 79:1982;5312-5316.
11. Assoian R.K., Komoriya A., Meyers C.A., Miller D.M., Sporn M.B. Transforming growth factor-β in human platelets. Identification of a major storage site, purification, and characterization. J. Biol. Chem. 258:1983;7155-7160.
12. Derynck R., Jarrett J.A., Chen E.Y., Eaton D.H., Bell J.R., Assoian R.K., Roberts A.B., Sporn M.B., Goeddel D.V. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature. 316:1985;701-705.
13. Derynck R., Lindquist P.B., Lee A., Wen D., Tamm J., Graycar J.L., Rhee L., Mason A.J., Miller D.A., Coffey R.J., Moses H.L., Chen E.Y. A new type of transforming growth factor-β, TGF-β3. EMBO J. 7:1988;3737-3743.
14. ten Dijke P., Hansen P., Iwata K.K., Pieler C., Foulkes J.G. Identification of another member of the transforming growth factor type β gene family. Proc. Natl. Acad. Sci. USA. 85:1988;4715-4719.
15. Barr P.J. Mammalian subtilisins: the long sought dibasic processing endoproteases. Cell. 66:1991;1-3.
16. Miyazono K., Hellman U., Wernstedt C., Heldin C.-H. Latent high molecular weight complex of transforming growth factor β1. Purification from human platelets and structural characterization. J. Biol. Chem. 263:1988;6407-6415.
17. Miyazono K., Olofsson A., Colosetti P., Heldin C.-H. A role of the latent TGF-β 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J. 10:1991;1091-1101.
18. Wakefield L.M., Smith D.M., Flanders K.C., Sporn M.B. Latent transforming growth factor-β from human platelets. A high molecular weight complex containing precursor sequences. J. Biol. Chem. 263:1988;7646-7654.
19. Harpel J.G., Metz C.N., Kojima S., Rifkin D.B. Control of transforming growth factor-β activity: latency versus activation. Progress in Growth Factor Research. 4:1992;321-335.
20. Massagué J. The transforming growth factor-β family. Ann. Rev. Cell Biol. 6:1990;597-641.
21. Kingsley D.M. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8:1994;133-146.
22. Hogan B.L.M. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 10:1996;1580-1594.
23. Daopin S., Piez K.A., Ogawa Y., Davies D.R. Crystal structure of transforming growth factor-β2: an unusual fold for the superfamily. Science. 257:1992;369-373.
24. Schlunegger M.P., Grütter M.G. An unusual feature revealed by the crystal structure at 2.2 A resolution of human transforming growth factor-β2. Nature. 358:1992;430-434.
25. Griffith D.L., Keck P.C., Sampath T.K., Rueger D.C., Carlson W.D. Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor β superfamily. Proc. Natl. Acad. Sci. USA. 93:1996;878-883.
26. Gray A.M., Mason A.J. Requirement for activin A and transforming growth factor-β1 pro-regions in homodimer assembly. Science. 247:1990;1328-1330.
27. Lopez A.R., Cook J., Deininger P.L., Derynck R. Dominant negative mutants of transforming growth factor-β1 inhibit the secretion of different transforming growth factor-β isoforms. Mol. Cell. Biol. 12:1992;1674-1679.
28. R. Derynck, Transforming growth factor-β, in: A. Thomson (Ed.), The Cytokine Handbook, 2nd edition, Academic Press, Boston, San Diego, 1994, pp. 319-342.
29. Derynck R. TGF-β receptor-mediated signaling. Trends Biochem. Sci. 19:1994;548-553.
30. Massagué J. TGF-β signaling: receptors, transducers, and Mad proteins. Cell. 85:1996;947-950.
31. Cheifetz S., Like B., Massagué J. Cellular distribution of type I and type II receptors for transforming growth factor-β J. Biol. Chem. 261:1986;9972-9978.
32. Cheifetz S., Weatherbee J.A., Tsang M.L.-S., Anderson J.K., Mole J.E., Lucas R., Massagué J. The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors. Cell. 48:1987;409-415.
33. Massagué J. Receptors for the TGF-β family. Cell. 69:1992;1067-1070.
34. Segarini P.R., Rosen D.M., Seyedin S.M. Binding of transforming growth factor-β to cell surface proteins varies with cell type. Mol. Endocrinol. 3:1989;261-272.
35. Boyd F.T., Massagué J. Transforming growth factor-β inhibition of epithelial cell proliferation linked to the expression of a 53 kDa membrane receptor. J. Biol. Chem. 264:1989;2272-2278.
36. Laiho M., Weis F.M.B., Massagué J. Concomitant loss of transforming growth factor (TGF)-β receptors types I and II in TGF-β-resistant cell mutants implicates both receptor types in signal transduction. J. Biol. Chem. 265:1990;18518-18524.
37. Laiho M., Weis F.M.B., Boyd F.T., Ignotz R.A., Massagué J. Responsiveness to transforming growth factor-β (TGF-β) restored by genetic complementation between cells defective in TGF-β receptors I and II. J. Biol. Chem. 266:1991;9108-9112.
38. Geiser A., Burmester J.K., Webbink R., Roberts A.B., Sporn M.B. Inhibition of growth by transforming growth factor-β following fusion of two non-responsive human carcinoma cell lines. J. Biol. Chem. 267:1992;2588-2593.
39. Massagué J. Subunit structure of a high affinity receptor for type β transforming growth factor. Evidence for a disulfide-linked glycosylated receptor complex. J. Biol. Chem. 260:1985;7059-7066.
40. Massagué J., Like B. Cellular receptors for type β transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J. Biol. Chem. 260:1985;2636-2645.
41. Fanger B.O., Wakefield L.M., Sporn M.B. Structure and properties of the cellular receptor for transforming growth factor type β Biochemistry. 25:1986;3083-3091.
42. Wang X.-F., Lin H.Y., Ng-Eaton E., Downward J., Lodish H.F., Weinberg R.A. Expression cloning and characterization of the TGF-β type III receptor. Cell. 67:1991;797-805.
43. Cheifetz S., Andres J.L., Massagué J. The transforming growth factor-β receptor type III is a membrane proteoglycan. Domain structure of the receptor. J. Biol. Chem. 263:1988;16984-16991.
44. Andres J.L., Stanley K., Cheifetz S., Massagué J. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-β J. Cell Biol. 109:1989;3137-3145.
45. Segarini P.R., Seyedin S.M. The high molecular weight receptor to transforming growth factor-β contains glycosaminoglycan chains. J. Biol. Chem. 263:1988;8366-8370.
46. López-Casillas F., Cheifetz S., Doody J., Andres J., Lane W.S., Massagué J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system. Cell. 67:1991;785-795.
47. López-Casillas F., Payne H.M., Andres J.L., Massagué J. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J. Cell Biol. 124:1994;557-568.
48. Segarini P.R., Roberts A.B., Rosen D.M., Seyedin S.M. Membrane binding characteristics of two forms of transforming growth factor-β J. Biol. Chem. 288:1987;14655-14662.
49. Cheifetz S., Massagué J. Transforming growth factor-β (TGF-β) receptor proteoglycan. Cell surface expression and ligand binding in the absence of glycosaminoglycan chains. J. Biol. Chem. 264:1989;12025-12028.
50. Andres J.L., Rönnstrandt L., Cheifetz S., Massagué J. Purification of the transforming growth factor-β (TGF-β) binding proteoglycan betaglycan. J. Biol. Chem. 266:1991;23282-23287.
51. Andres J.L., DeFalcis D., Noda M., Massagué J. Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J. Biol. Chem. 267:1992;5927-5930.
52. Lamarre J., Vasudevan J., Gonias S.L. Plasmin cleaves betaglycan and releases a 60 kDa transforming growth factor-β complex from the cell surface. Biochem. J. 302:1994;199-205.
53. Pepin M.-C., Beauchemin M., Collins C., Plamondon J., O'Connor-McCourt M.D. Mutagenesis analysis of the membrane-proximal ligand binding site of the TGF-β receptor type III extracellular domain. FEBS Letters. 377:1995;368-372.
54. Yamaguchi Y., Mann D.M., Ruoslahti E. Negative regulation of transforming growth factror-β by the proteoglycan decorin. Nature. 346:1990;281-284.
55. Fukushima D., Butzow R., Hildebrand A., Ruoslahti E. Localization of transforming growth factor β binding site in betaglycan. J. Biol. Chem. 268:1993;22710-22715.
56. Gougos A., Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J. Biol. Chem. 265:1990;8361-8364.
57. Cheifetz S., Bellón T., Calés C., Vera S., Bernabeu C., Massagué J., Letarte M. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J. Biol. Chem. 267:1992;19027-19030.
58. Yamashita H., Ichijo H., Grimsby S., Morén A., ten Dijke P., Miyazono K. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-β J. Biol. Chem. 269:1994;1995-2001.
59. Bellón T., Corbi A., Lastres P., Calés C., Cebrián M., Vera S., Cheifetz S., Massagué J., Letarte M., Bernabeu C. Identification and expression of two forms of the human transforming growth factor-β-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23:1993;2340-2345.
60. Lastres P., Martín-Perez J., Langa C., Bernabeu C. Phosphorylation of the human transforming growth factor-β binding protein endoglin. Biochem. J. 301:1994;765-768.
61. McCarthy S.A., Bicknell R. Activin-A binds to a heterotrimeric receptor complex on the vascular endothelial cell surface. Evidence for a type III receptor. J. Biol. Chem. 269:1994;3909-3912.
62. Henis Y.I., Moustakas A., Lin H.Y., Lodish H.F. The types II and III transforming growth factor-β receptors form homo-oligomers. J. Cell Biol. 126:1994;139-154.
63. Pepin M.-C., Beauchemin M., Plamondon J., O'Connor-McCourt M.D. Mapping of the ligand binding domain of the transforming growth factor β receptor type III by deletion mutagenesis. Proc. Natl. Acad. Sci. USA. 91:1994;6997-7001.
64. Gougos A., Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J. Immunol. 141:1988;1925-1933.
65. Kaname S., Ruoslahti E. Betaglycan has multiple binding sites for transforming growth factor-β1. Biochem. J. 315:1996;815-820.
66. López-Casillas F., Wrana J.L., Massagué J. Betaglycan presents ligand to the TGF-β signaling receptor. Cell. 73:1993;1435-1444.
67. Moustakas A., Lin H.Y., Henis Y.I., Plamondon J., O'Connor-McCourt M.D., Lodish H.F. The transforming growth factor receptors types I, II and III form hetero-oligomeric complexes in the presence of ligand. J. Biol. Chem. 268:1993;22215-22218.
68. Zhang H., Shaw A.R.E., Mak A., Letarte M. Endoglin is a component of the transforming growth factor (TGF)-β receptor complex of human pre-leukemic cells. J. Immunol. 156:1996;565-573.
69. McAllister K.A., Grogg K.M., Johnson D.W., Gallione C.J., Baldwin M.A., Jackson C.E., Helmbold E.A., Markel D.S., McKinnon W.C., Murrell J., McKormick M.K., Pericak-Vance M.A., Heutink P., Oostra B.A., Haitjema T., Westerman C.J.J., Porteous M., Guttmacher A.E., Letarte M., Marchuk D.A. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Genet. 8:1994;345-351.
70. Lastres P., Letamendía A., Zhang H., Rius C., Almendro N., Raab U., López L.A., Langa C., Fabra A., Letarte M., Bernabéu C. Endoglin modulates cellular responses to TGF-β1. J. Cell Biol. 133:1996;1109-1121.
71. Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase receptor. Cell. 68:1992;775-785.
72. Lawler S., Candia A.F., Ebner R., Lopez A.R., Moses H.L., Wright C.V.E., Derynck R. The murine type II TGF-β receptor has a coincident embryonic expression and binding preference for TGF-β1. Development. 120:1994;165-175.
73. Suzuki A., Shioda N., Maeda T., Tada M., Ueno N. Cloning of an isoform of mouse TGF-β type II receptor gene. FEBS Letters. 355:1994;19-22.
74. Mathews L.S., Vale W.W. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell. 65:1991;973-982.
75. Attisano L., Wrana J.L., Cheifetz S., Massagué J. Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell. 68:1992;97-108.
76. Mathews L.S., Vale W.W., Kintner C.R. Cloning of a second type of activin receptor and functional characterization in Xenopus embryos. Science. 255:1992;1702-1705.
77. Liu F., Ventura F., Doody J., Massagué J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol. Cell. Biol. 15:1995;3479-3486.
78. Nohno T., Ishikawa T., Saito T., Hosokawa K., Noji S., Wolsing D.H., Rosenbaum J.S. Identification of a human type II receptor for bone morphogenetic protein-4 that differential heteromeric complexes with bone morphogenetic protein type I receptors. J. Biol. Chem. 270:1995;22522-22526.
79. Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H., ten Dijke P., Heldin C.-H., Miyazono K. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. USA. 92:1995;7632-7636.
80. Baarends W.M., van Helmond M.J.L., Post M., van der Schoot P.J.C.M., Hoogerbrugge J.W., de Winter J.P., Uilenbroek J.T.J., Karels B., Wilming L.G., Meijers J.H.C., Themmen A.P.N., Grotegoed J.A. A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Müllerian duct. Development. 120:1994;189-197.
81. di Clemente N., Wilson C., Faure E., Boussin L., Carmillo P., Tizard R., Picard J.-Y., Vigier B., Josso N., Cate R. Cloning, expression and alternative splicing of the receptor for anti-müllerian hormone. Mol. Endocrinol. 8:1994;1006-1020.
82. Estevez M., Attisano L., Wrana J.L., Albert P.S., Massagué J., Riddle D.L. The daf-4 gene encodes a bone morphogenetic protein receptor controlling C. elegans dauer larva development. Nature. 365:1993;644-649.
83. Letsou A., Arora K., Wrana J.L., Simin K., Twombly V., Jamal J., Staehling-Hampton K., Hoffman F.M., Gelbart W.M., Massagué J., O'Connor M.B. Drosophila dpp signaling is mediated by the punt gene product: a dual ligand-binding type II receptor of the TGF-β receptor family. Cell. 80:1995;899-908.
84. Ruberte E., Marty T., Nellen D., Affolter M., Basler K. An absolute requirement for both the type II and type I receptors, punt and thick veins, for dpp signaling in vivo. Cell. 80:1995;889-897.
85. Lin H.Y., Moustakas A., Knaus P., Wells R.G., Henism Y.I., Lodish H.F. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-β receptor. A heterogeneous glycosylated protein with high affinity and selectivity for TGF-β ligands. J. Biol. Chem. 270:1995;2747-2754.
86. Rodriguez C., Chen F., Weinberg R.A., Lodish H.F. Cooperative binding of transforming growth factor (TGF)-β2 to the types I and II TGF-β receptors. J. Biol. Chem. 270:1995;15919-15922.
87. Hoodless P.A., Haerry T., Abdollah S., Stapleton M., O'Connor M.B., Attisano L., Wrana J.L. MADR1, a MAD-related protein that functions in BMP2 signalling pathways. Cell. 85:1996;489-500.
88. Yamashita H., ten Dijke P., Huylebroek D., Sampath T.K., Andries M., Smith J.C., Heldin C.-H., Miyazono K. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J. Cell Biol. 130:1995;217-226.
89. Nishitoh H., Ichijo H., Kimura M., Matsumoto T., Makashima F., Yamaguchi A., Yamashita H., Enomoto S., Miyazono K. Identification of type I and type II receptors for Growth/Differentiation Factor-5. J. Biol. Chem. 271:1996;21345-21352.
90. Kawabata M., Chytil A., Moses H.L. Cloning of a novel type II serine/threonine kinase receptor through interaction with the type I transforming growth factor-β receptor. J. Biol. Chem. 270:1995;5625-5630.
91. Childs S.R., Wrana J.L., Arora K., Attisano L., O'Connor M.B., Massagué J. Identification of a Drosophila activin receptor. Proc. Natl. Acad. Sci. USA. 90:1993;9475-9479.
92. Chen R.-H., Derynck R. Homomeric interactions between the type II TGF-β receptors. J. Biol. Chem. 269:1994;22868-22874.
93. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 241:1988;42-52.
94. Hanks S.K., Hunter T. Protein kinases VI. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9:1995;576-596.
95. Mathews L.S., Vale W.W. Characterization of type II activin receptors. Binding, processing and phosphorylation. J. Biol. Chem. 268:1993;19013-19018.
96. Wrana J.L., Attisano L., Wieser R., Ventura F., Massagué J. Mechanism of activation of the TGF-β receptor. Nature. 370:1994;341-347.
97. Chen F., Weinberg R.A. Biochemical evidence for the autophosphorylation and transphosphorylation of transforming growth factor-β receptor kinases. Proc. Natl. Acad. Sci. USA. 92:1995;1565-1569.
98. Souchelnytskyi S., ten Dijke P., Miyazono K., Heldin C.-H. Phosphorylation of Ser165 in TGF-β type I receptor modulates TGF-β1-induced cellular responses. EMBO J. 15:1996;6231-6240.
99. Luo K., Zhou P., Lodish H.F. The specificity of the transforming growth factor β receptor kinases determined by a spatially addressable peptide library. Proc. Natl. Acad. Sci. USA. 92:1995;11761-11765.
100. Nakamura T., Sugino K., Kurosawa N., Sawai M., Takio K., Eto Y., Iwashita S., Muramatsu M., Titani K., Sugino H. J. Biol. Chem. 267:1992;18924-18928.
101. S. Lawler, X.-H. Feng, R.-H. Chen, E.M. Maruoka, C.W. Turck, I. Griswold-Prenner, R. Derynck, The type II TGF-β receptor autophosphorylates not only on serine and threonine but also on tyrosine residues, J. Biol. Chem. (1997) in press.
102. ten Dijke P., Ichijo H., Franzén P., Schulz P., Saras J., Toyoshima H., Heldin C.-H., Miyazono K. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene. 8:1993;2879-2887.
103. ten Dijke P., Yamashita H., Ichijo H., Franzén P., Laiho M., Miyazono K., Heldin C.-H. Characterization of type I receptors for transforming growth factor-β and activin. Science. 264:1994;101-104.
104. He W.W., Gustafson M.L., Hirobe S., Donahoe P.K. Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-β type II receptor family. Dev. Dynamics. 196:1993;1333-1342.
105. Franzén P., ten Dijke P., Ichijo H., Yamasita H., Schulz P., Heldin C.-H., Miyazono K. Cloning of TGF-β type I receptor that forms a heteromeric complex with the TGF-β type II receptor. Cell. 75:1993;681-692.
106. Attisano L., Cárcamo J., Ventura F., Weis F.M.B., Massagué J., Wrana J.L. Identification of human activin and TGF-β type I receptors that form heteromeric kinase complexes with type II receptors. Cell. 75:1993;671-680.
107. Ebner R., Chen R.-H., Shum L., Lawler S., Zioncheck T., Lopez A.R., Derynck R. Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor. Science. 260:1993;1344-1348.
108. Rydén M., Imamura T., Jörnvall H., Belluardo N., Neveu I., Trupp M., Okadome T., ten Dijke P., Ibanez C.F. A novel type I receptor serine-threonine kinase predominantly expressed in the adult central nervous system. J. Biol. Chem. 271:1996;30603-30609.
109. Tsuchida K., Sawchenko P.E., Nishikawa S., Vale W.W. Molecular cloning of a novel type I receptor serine/threonine kinase for the TGF β superfamily from rat brain. Mol. Cell. Neurosci. 7:1996;467-478.
110. Ebner R., Chen R.-H., Lawler S., Zioncheck T., Derynck R. Determination of type I receptor ligand specificity by the type II receptors for TGF-β or activin. Science. 288:1993;900-902.
111. C.H. Bassing, J.M. Yingling, D.J. Howe, T. Wang, W.W. He, M.L. Gustafson, P. Shah, P.K. Donahoe, X.-F. Wang, A transforming growth factor β type I receptor that signals to activate gene expression, Science 263, 87-89.
112. Miettinen P.J., Ebner R., Lopez A.R., Derynck R. TGF-β-induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol. 127:1994;2021-2036.
113. Tsuchida K., Mathews L., Vale W.W. Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor. Proc. Natl. Acad. Sci. USA. 90:1993;11242-11246.
114. Cárcamo J., Weis F.M.B., Ventura F., Wieser R., Wrana J., Attisano L., Massagué J. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor-β and activin. Mol. Cell. Biol. 14:1994;3810-3821.
115. ten Dijke P., Yamashita H., Sampath T.K., Reddi A.H., Estevez M., Riddle D.L., Ichijo H., Heldin C.-H., Miyazono K. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J. Biol. Chem. 269:1994;16985-16988.
116. Koenig B.B., Cook J.S., Wolsing D.H., Ting J., Tiesman J.P., Correa P.E., Olson C.A., Pecquet A.L., Ventura F., Grant R.A., Chen G.-X., Wrana J.L., Massagué J., Rosenbaum J.S. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol. Cell. Biol. 14:1994;5961-5974.
117. Suzuki A., Thies R.S., Yamaji N., Song J.J., Wozney J.M., Murakami K., Ueno N. A truncated bone morphogenetic protein receptor affects dorsal-ventral patterning in the early Xenopus embryo. Proc. Natl. Acad. Sci. USA. 91:1994;10255-10259.
118. Georgi L.L., Albert P.S., Riddle D.L. daf-1, a C. elegans gene controlling dauer larva development, encodes a novel receptor protein kinase. Cell. 61:1990;635-645.
119. Brummel T.J., Twombly V., Marques G., Wrana J.L., Newfeld S.J., Attisano L., Massagué J., O'Connor M.B., Gelbart W.M. Characterization and relationship of dpp receptors encoded by the saxophone and thick veins genes in Drosophila. Cell. 78:1994;251-261.
120. Wrana J.L., Tran H., Attisano L., Arora K., Childs S.R., Massagué J., O'Connor M.B. Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an activin receptor complex. Mol. Cell. Biol. 14:1994;944-950.
121. Nellen D., Affolter M., Basler K. Receptor serine/threonine kinases implicated in the control of Drosophila body pattern by decapentaplegic. Cell. 78:1994;225-237.
122. Penton A., Chen Y., Staehling-Hampton K., Wrana J.L., Attisano L., Szidonya J., Cassill J.A., Massagué J., Hoffmann F.M. Identification of two bone morphogenetic protein type I receptors in Drosophila and evidence that Brk25D is a decapentaplegic receptor. Cell. 78:1994;239-250.
123. Xie T., Finelli A.L., Padgett R.W. The Drosophila saxophone gene: a serine-threonine kinase receptor of the TGF-β superfamily. Science. 263:1994;1756-1759.
124. Macias-Silva M., Abdollah S., Hoodless P., Pirone R., Attisano L., Wrana J.L. MADR-2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell. 87:1996;1215-1224.
125. Wrana J.L., Attisano L., Cárcamo J., Zentella A., Doody J., Laiho M., Wang X.-F., Massagué J. TGF-β signals through a heteromeric protein kinase receptor complex. Cell. 71:1992;1003-1014.
126. Yamashita H., ten Dijke P., Franzén P., Miyazono K., Heldin C.-H. Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-β J. Biol. Chem. 269:1994;20172-20178.
127. Weis-Garcia F., Massagué J. Complementation between kinase-defective and activation-defective TGF-β receptors reveals a novel form of receptor cooperativity essential for signaling. EMBO J. 15:1996;276-289.
128. Luo K., Lodish H.F. Signaling by chimeric erythropoietin-TGF-β receptors: homodimerization of the cytoplasmic domain of the type I TGF-β receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction. EMBO J. 15:1996;4485-4496.
129. Attisano L., Wrana J.L., Montalvo E., Massagué J. Activation of signalling by the activin receptor complex. Mol. Cell. Biol. 16:1996;1066-1073.
130. Chen R.-H., Moses H.L., Maruoka E.M., Derynck R., Kawabata M. Phosphorylation-dependent interaction of the cytoplasmic domains of the type I and type II TGF-β receptors. J. Biol. Chem. 270:1995;12235-12241.
131. Ventura F., Doody J., Liu F., Wrana J.L., Massagué J. Reconstitution and transphosphorylation of TGF-β receptor complexes. EMBO J. 13:1994;5581-5589.
132. Feng X.-H., Derynck R. Ligand-independent activation of TGF-β signaling pathways by heteromeric cytoplasmic domains of TGF-β receptors. J. Biol. Chem. 271:1996;13123-13129.
133. Wu X., Robinson C.E., Fong H.W., Gimble J.M. Analysis of the native murine bone morphogenetic protein serine threonine kinase type I receptor (ALK-3). J. Cell Physiol. 168:1996;453-461.
134. Wieser R., Wrana J.L., Massagué J. GS domain mutations that constitutively activate TβRI, the downstream signaling component in the TGF-β receptor complex. EMBO J. 14:1995;2199-2208.
135. Keeton M.R., Curriden S.A., van Zonneveld A., Loskutoff D.J. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor β J Biol Chem. 266:1991;23048-23052.
136. Feng X.-H., Filvaroff E.H., Derynck R. Transforming growth factor-β (TGF-β)-induced down-regulation of cyclin A expression requires a functional TGF-β receptor complex. Characterization of chimeric and truncated type I and type II receptors. J. Biol. Chem. 270:1995;24237-24245.
137. Okadome T., Yamashita H., Franzén P., Morén A., Heldin C.-H., Miyazono K. Distinct roles of the intracellular domains of transforming growth factor-β type I and type II receptors in signal transduction. J. Biol. Chem. 269:1994;30753-30756.
138. D. Vivien, L. Attisano, J.L. Wrana, J. Massagué, Signaling activity of homologous and heterologous transforming growth factor-β receptor kinase complexes, J. Biol. Chem. 270, 7134-7141.
139. Chen R.-H., Ebner R., Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science. 260:1993;1335-1338.
140. Brand T., McClelland W.R., Schneider M.D. A dominant negative receptor for type β transforming growth factor created by deletion of the kinase domain. J. Biol. Chem. 268:1993;11500-11503.
141. Wieser R., Attisano L., Wrana J.L., Massagué J. Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region. Mol. Cell. Biol. 13:1993;7239-7247.
142. Brand T., Schneider M.D. Inactive type II and type I receptors for TGF-β are dominant negative inhibitors of TGF-β-dependent transcription. J. Biol. Chem. 270:1995;8274-8284.
143. Knighton D., Zheng J., ten Eyck L., Ashford V., Xuong N.-H., Taylor S., Sowadski J. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 253:1991;407-414.
144. Cárcamo J., Zentella A., Massagué J. Disruption of transforming growth factor β signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol. Cell. Biol. 15:1995;1573-1581.
145. Marshall C.J. Signal transduction: hot lips and phosphorylation of protein kinases. Nature. 367:1994;686.
146. X.-H. Feng, R. Derynck, A kinase subdomain of transforming growth factor-β (TGF-β) type i receptor determines the TGF-β intracellular signaling specificity, EMBO J. (1997) in press.
147. Saitoh M., Nishitoh H., Amagasa T., Miyazono K., Takagi M., Ichijo H. Identification of important regions in the cytoplasmic juxtamembrane domain of type I receptor that separate signaling pathways of transforming growth factor-β J. Biol. Chem. 271:1996;2769-2775.
148. Pietenpol J.A., Stein R.W., Moran E., Yaciuk P., Schlegel R., Lyons R.M., Pittelkow M.R., Munger K., Howley P.M., Moses H.L. TGF-β1 inhibition of c-myc transcription and growth in kerartinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell. 61:1990;777-785.
149. Laiho M., Rönnstrand L., Heino J., DeCaprio J.A., Ludlow J.W., Livingston D.M., Massagué J. Control of junB and extracellular matrix protein expression by transforming growth factor-β 1 is independent of simian virus 40 T antigen-sensitive growth-sensitive growth-inhibitory events. Mol. Cell. Biol. 11:1991;972-978.
150. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
151. Weinberg R.A. E2F and cell proliferation: a world turned upside down. Cell. 85:1996;457-459.
152. KIP1 by the viral E1A oncoprotein in TGF-β-treated cells. Nature. 380:1996;265-288.
153. Fafeur V., O'Hara B., Böhlen P. A glycosylation-deficient cell mutant with modified responses to transforming growth factor-β and other growth inhibitory cytokines: evidence for multiple growth inhibitory signal transduction pathways. Mol. Biol. Cell. 4:1993;135-144.
154. Centrella M., Casinghino S., Kim J., Pham T., Rosen V., Wozney J., McCarthy T.L. Independent changes in type I and type II receptors for transforming growth factor-β induced by bone morphogenetic protein parallel expression of the osteoblast phenotype. Mol. Cell. Biol. 15:1995;3273-3281.
155. Leof E.B., Proper J.A., Goustin A.S., Shipley G.D., DiCorleto P.E., Moses H.L. Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. Proc. Natl. Acad. Sci. USA. 83:1986;2453-2457.
156. Centrella M., McCarthy T.L., Canalis E. Transforming growth factor-β is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. J. Biol. Chem. 288:1987;2869-2874.
157. Battegay E.J., Raines E.W., Seifert R.A., Bowen-Pope D.F., Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 63:1990;515-524.
158. Ridley A.J., Davis J.B., Stroobant P., Land H. Transforming growth factors-β1 and β2 are mitogens for rat Schwann cells. J. Cell Biol. 109:1989;3419-3424.
159. Soma Y., Grotendorst G.R. TGF-β stimulates primary human skin fibroblast DNA synthesis via an autocrine production of PDGF-related peptides. J. Cell. Physiol. 140:1989;246-253.
160. Igarashi A., Okochi H., Bradham D.M., Grotendorst G.R. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell. 4:1993;637-645.
161. Assoian R.K., Frolik C.A., Roberts A.B., Miller D.M., Sporn M.B. Transforming growth factor-β controls receptor levels for epidermal growth factor in NRK fibroblasts. Cell. 36:1984;35-41.
162. A.B. Roberts, M.B. Sporn, The transforming growth factor-βs, in: M.B. Sporn, A.B. Roberts (Eds.), Peptide Growth Factors and their Receptors, Springer Verlag, Heidelberg, 1990, pp. 421-472.
163. Roberts A.B., McCune B.K., Sporn M.B. TGF-β: regulation of extracellular matrix. Kidney Int. 41:1992;557-559.
164. Morton D.M., Barrack E.R. Modulation of transforming growth factor
165. Herrera R.E., Mäkelä T.P., Weinberg R.A. TGF-β-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein. Mol. Biol. Cell. 7:1996;1335-1342.
166. Laiho M., DeCaprio J.A., Ludlow J.W., Livingston D.M., Massagué J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell. 62:1990;175-185.
167. Geng Y., Weinberg R.A. Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc. Natl. Acad. Sci. USA. 90:1993;10315-10319.
168. Sherr C.J. D-type cyclins. Trends Biochem. Sci. 20:1995;187-190.
169. Ewen M.E., Sluss H.K., Whitehouse L.L., Livingston D.M. TGF-β inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell. 74:1993;1009-1020.
170. Koff A., Ohtsuki M., Polyak K., Roberts J.M., Massagué J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β Science. 260:1993;536-539.
171. Hunter T., Pines J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell. 79:1994;573-582.
172. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
173. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature. 371:1994;257-261.
174. Reynisdóttir I., Polyak K., Iavarone A., Massagué J. Kip/Cip and Ink4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β Genes Dev. 9:1995;1831-1845.
175. Datto M.B., Li Y., Panus J.F., Howe D.J., Xiong Y., Wang X.-F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA. 92:1995;5545-5549.
176. Kramer I.M., Koornneef I., de Laat S.W., van den Eijnden-van Raaij A.J. TGF-β1 induces phosphorylation of the cyclic AMP responsive element binding protein in ML-CCL64 cells. EMBO J. 10:1991;1083-1089.
177. Alevizopoulos A., Dusserre Y., Tsai-Pflugfelder M., von der Weid T., Wahli W., Mermod N. A proline-rich TGF-β-responsive transcriptional activator interacts with histone H3. Genes Dev. 9:1995;3051-3066.
178. Brown E.J., Schreiber S.L. A signaling pathway to translational control. Cell. 86:1996;517-520.
179. Kay J.E. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem. J. 314:1996;361-385.
180. Wang T., Donahoe P.K., Zervos A.S. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science. 265:1994;674-676.
181. Wang T., Li B.-Y., Danielson P.D., Shah P.C., Rockwell S., Lechleider R.J., Martin J., Manganaro T., Donahoe P.K. The immunophilin FKBP12 functions as a common inhibitor of the TGF-β family type I receptors. Cell. 86:1996;435-444.
182. Okadome T., Oeda E., Saitoh M., Ichijo H., Moses H.L., Miyazono K., Kawabata M. Characterization of the interaction of FKBP12 with the transforming growth factor-β type I receptor in vivo. J. Biol. Chem. 271:1996;21687-21690.
183. M.-J. Charng, P. Kinnunen, J. Hawker, T. Brand, M.D. Schneider, FKBP-12 recognition is dispensable for signal generation by type I transforming growth factor-β receptors, J. Biol. Chem. 271, 22941-22944.
184. Kawabata M., Imamura T., Miyazono K., Engel M.E., Moses H.L. Interaction of the transforming growth factor-β type I receptor with farnesyl transferase-α J. Biol. Chem. 270:1995;29628-29631.
185. Wang T., Danielson P.D., Li B., Shah P.C., Kim S.D., Donahoe P.K. The p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin signaling. Science. 271:1996;1120-1122.
186. Ventura F., Liu F., Doody J., Massagué J. Interaction of transforming growth factor-β receptor I with farnesyl-protein transferase-α in yeast and mammalian cells. J. Biol. Chem. 271:1996;13931-13934.
187. Chen R.-H., Miettinen P.J., Maruoka E.M., Choy L., Derynck R. A WD-domain protein that is associated with and phosphorylated by the type II TGF-β receptor. Nature. 377:1995;548-552.
188. Reddy K.B., Karode M.C., Harmony J.A.K., Howe P.H. Interaction of transforming growth factor β receptors with apolipoprotein J/clusterin. Biochemistry. 35:1996;309-314.
189. ras by transforming growth factor β in epithelial cells. J. Biol. Chem. 267:1992;5029-5031.
190. Yan Z., Winawer S., Friedman E. Two different signal transduction pathways can be activated by transforming growth factor β1 in epithelial cells. J. Biol. Chem. 269:1994;13231-13237.
191. mapk in proliferating cultures of epithelial cells. J. Biol. Chem. 270:1995;7117-7124.
192. Mucsi I., Skorecki K.L., Goldberg H.J. Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-β1 on gene expression. J. Biol. Chem. 271:1996;16567-16572.
193. Chatani Y., Tanimura S., Miyoshi N., Hattori A., Sato M., Kohno M. Cell type-specific modulation of cell growth by TGF-β1 does not correlate with mitogen-activated protein kinase activation. J. Biol. Chem. 270:1995;30686-30692.
194. Atfi A., Lepage K., Allard P., Chapdelaine A., Chevalier S. Activation of a serine/threonine kinase signaling patway by transforming growth factor type β Proc. Natl. Acad. Sci. USA. 92:1995;12110-12114.
195. Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Oishi I., Ueno N., Taniguchi T., Nishida E., Matsumoto K. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science. 270:1995;2008-2011.
196. Shibuya H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y., Ueno N., Irie N., Nishida E., Matsumoto K. TAB1: an activator of TAK1 MAPKKK in TGF-β signal transduction. Science. 272:1996;1179-1182.
197. Moriguchi T., Kuroyanagi N., Yamaguchi K., Gotoh Y., Irie K., Kano T., Shirakabe K., Muro Y., Shibuya H., Matsumoto K., Nishida E., Hagiwara M. A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J. Biol. Chem. 271:1996;13675-13679.
198. Halstead J., Kemp K., Ignotz R.A. Evidence for an involvement of phosphatidyl choline-phospholipase C and protein kinase C in transforming growth factor-β signaling. J. Biol. Chem. 270:1995;13600-13603.
199. Ohtsuki M., Massagué J. Evidence for the involvement of protein kinase activity in transforming growth factor-β signal transduction. Mol. Cell. Biol. 12:1992;261-265.
200. Howe P.H., Bascom C.C., Cunningham M.R., Leof E.B. Regulation of transforming growth factor β1 action by multiple transducing pathways: evidence for both G protein-dependent and-independent signaling. Cancer Res. 49:1989;6024-6031.
201. α1. J. Biol. Chem. 268:1993;19851-19857.
202. Gruppuso P.A., Mikumo R., Brautigan D.L., Braun L. Growth arrest induced by trnasforming growth factor beta 1 is accompanied by protein phosphatase activation in human keratinocytes. J. Biol. Chem. 266:1991;3444-3448.
203. Vogel W., Lammers R., Huang J., Ullrich A. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science. 259:1993;1611-1614.
204. Klingmuller U., Lorenz U., Cantley L.C., Neel B.G., Lodish H.F. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell. 80:1995;729-738.
205. Stone J.M., Collinge M.A., Smith R.D., Horn M.A., Walker J.C. Interaction of a protein phosphatase with an Arabidopsis serine-threonine receptor kinase. Science. 266:1994;793-796.
206. Raftery L.A., Twombly V., Wharton K., Gelbart W.M. Genetic screens to identify elements of the decapentaplegic signaling pathway in Drosophila. Genetics. 139:1995;241-254.
207. Sekelsky J.J., Newfeld S.J., Raftery L.A., Chartoff E.H., Gelbart W.M. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics. 139:1995;1347-1358.
208. Wiersdorff V., Lecuit T., Cohen S.M., Mlodzik M. Mad acts downstream of Dpp receptors, revealing a differential requirement for dpp signaling in initiation and propagation of morphogenesis in the Drosophila eye. Development. 122:1996;2153-2162.
209. Newfeld S.J., Chartoff E.H., Graff J.M., Melton D.A., Gelbart W.M. Mothers against dpp encodes a conserved cytoplasmic protein required in DPP/TGF-β responsive cells. Development. 122:1996;2099-2108.
210. Savage C., Das P., Finelli A.L., Townsend S.R., Sun C.Y., Baird S.E., Padgett R.W. Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor β pathway components. Proc. Natl. Acad. Sci. U.S.A. 93:1996;790-794.
211. Derynck R., Zhang Y. The Mad way to do it. Curr. Biol. 6:1996;1226-1229.
212. Wrana J.L., Attisano L. MAD-related proteins in TGF-β signalling. Trends Genet. 12:1996;493-496.
213. Derynck R., Gelbart W.M., Harland R.M., Heldin C.-H., Kern S.E., Massagué J., Melton D.A., Mlodzik M., Padgett R.W., Roberts A.B., Smith J., Thomsen G.H., Vogelstein B., Wang X.-F. Nomenclature: vertebrate mediators of TGF-β family signals. Cell. 87:1996;173.
214. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:1996;350-353.
215. Graff J.M., Bansal A., Melton D.A. Xenopus Mad proteins transduce distinct subsets of signals for the TGF-β superfamily. Cell. 85:1996;479-487.
216. Liu F., Hata A., Baker J.C., Doody J., Cárcamo J., Harland R.M., Massagué J. A human Mad protein acting as a BMP-regulated transcriptional activator. Nature. 381:1996;620-623.
217. Thomsen G.H. Xenopus mothers against decapentaplegic is an embryonic ventralizing agent that acts downstream of the BMP-2/4 receptor. Development. 122:1996;2359-2366.
218. Baker J.C., Harland R.M. A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway. Genes Dev. 10:1996;1880-1889.
219. Eppert K., Scherer S.W., Ozcelik H., Pirone R., Hoodless P., Kim H., Tsui L.-C., Bapat B., Gallinger S., Andrulis I.L., Thomsen G.H., Wrana J.L., Attisano L. MADR2 maps to 18q21 and encodes a TGF-β-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 86:1996;543-552.
220. Zhang Y., Feng X.-H., Wu R.-Y., Derynck R. Receptor-associated Mad homologs synergize to induce TGF-β response. Nature. 382:1996;168-172.
221. Lagna G., Hata A., Hemmati-Brivanlou A., Massagué J. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways. Nature. 383:1996;832-836.
222. Chen Y., Lebrun J.-J., Vale W. Regulation of transforming growth factor-β- and activin-induced transcription by mammalian Mad proteins. Proc. Natl. Acad. Sci. USA. 93:1996;12992-12997.
223. Zhang Y., Musci T., Derynck R. The tumor suppressor Smad 4/DPC 4 as a central mediator of Smad function: cooperativity with other Smads and interference of a Smad 4/DPC 4 mutant with nuclear translocation of Smads. Curr. Biol. 7:1997;270-276.
224. Lechleider R.J., de Caestecker M.P., Dehejia A., Polymeropoulos M.H., Roberts A.B. Serine phosphorylation, chromosomal localization, and transforming growth factor-β signal transduction by human bsp-1. J. Biol. Chem. 271:1996;17617-17620.
225. Yingling J.M., Das P., Savage C., Zhang M., Padgett R.W., Wang X.-F. Mammalian dwarfins are phosphorylated in response to transforming growth factor β and are implicated in control of cell growth. Proc. Natl. Acad. Sci. USA. 93:1996;8940-8944.
226. Wu R.-Y., Zhang Y., Feng X.-H., Derynck R. Homomeric and heteromeric interactions are required for signaling activity and functional cooperativity of Smad-3 and -4. Mol. Cell. Biol. 17:1997;2521-2528.
227. Arora K., Dai H., Kazuko S.G., Jamal J., O'Connor M.B., Letsou A., Warrior R. The Drosophila schnurri gene acts in the Dpp/TGF β signaling pathway and encodes a transcription factor homologous to the human MBP family. Cell. 81:1995;781-790.
228. Grieder N.C., Nellen D., Burke R., Basler K., Affolter M. Schnurri is required for Drosophila Dpp signaling and encodes a zinc finger protein similar to the mammalian transcription factor PRDII-BF1. Cell. 81:1995;791-800.
229. de Celis J.F., Barrio R., Kafatos F.C. A gene complex acting downstream of dpp in Drosophila wing morphogenesis. Nature. 381:1996;421-424.
230. Chen X., Rubock M.J., Whitman M. A transcriptional partner for MAD proteins in TGF-β signaling. Nature. 383:1996;691-696.
231. B.A. Arrick, R. Derynck, The biological role of transforming growth factor-β in cancer development, in: J. Waxman (Ed.), Molecular Endocrinology of Cancer, Cambridge University Press, 1996, pp. 51-78.
232. Markowitz S.D., Roberts A.B. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine and Growth Factor Reviews. 7:1996;93-102.
233. Park J., Kim S.-J., Bang Y.-J., Park J.-G., Kim N.K., Roberts A.B., Sporn M.B. Genetic changes in the transforming growth factor-β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β Proc. Natl. Acad. Sci. USA. 91:1994;8772-8776.
234. Hoosein N.M., McKnight M.K., Levine A.E., Mulder K.M., Childress K.E., Brattain M.G. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-β1. Exp. Cell Res. 181:1989;442-453.
235. Damstrup L., Rygaard K., Spang-Thomsen M., Poulson H.S. Expression of transforming growth factor-β (TGF-β) receptors and expression of TGF-β1, TGF-β2, and TGF-β3 in human small cell cancer cell lines. Br. J. Cancer. 67:1993;1015-1021.
236. Manning A., Williams A., Game S., Pareskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor β (TGF β): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF β Oncogene. 6:1991;1471-1476.
237. Markowitz S., Myeroff L., Cooper M.J., Traicoff J., Kochera M., Lutterbaugh J., Swiriduk M., Willson J.K. A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-β independence without inactivating the p53 tumor suppressor gene. J. Clin. Invest. 93:1994;1005-1013.
238. Wang J., Sun L., Meyeroff L., Wang X.-F., Gentry L.E., Yang J., Liang J., Zborowska E., Markowitz S., Willson J.K.V., Brattain M.G. Demonstration that mutation of the type II TGF-β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J. Biol. Chem. 270:1995;22044-22049.
239. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B., Brattain M.G., Willson J.K.V. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
240. Myeroff L., Parsons R., Kim S.-J., Hedrick L., Cho K., Orth K., Mathis M., Kinzler K.W., Lutterbaugh J., Park K., Barg Y.-J., Lee H., Park J.-G., Lynch H., Roberts A., Vogelstein B., Markowitz S.A. A TGF-β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 55:1995;5545-5547.
241. Eshelman J., Markowitz S. Microsatellite instability in inherited and sporadic neoplasms. Curr. Opin. Oncol. 7:1995;83-89.
242. Parsons R., Myeroff L., Liu B., Willson J.K.V., Markowitz S.D., Kinzler K.W., Vogelstein B. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res. 55:1995;5548-5550.
243. L. Garrigue-Antar, T. Munoz-Antonia, S.J. Antonia, J. Gesmonde, V.F. Velluci, M. Reiss, Missense mutations of the transforming growth factor-β type II receptor in human head and neck squamous carcinoma cells, Cancer Res. (1995) 3982-3987.
244. Knaus P.I., Lindemann D., DeCoteau J.F., Perlman R., Yankelev H., Hille M., Kadin M.E., Lodish H.F. A dominant inhibitory mutant of the type II transforming growth factor β receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol. Cell. Biol. 16:1996;3480-3489.
245. Sun L., Wu G., Willson J.K.V., Zborowska E., Yang J., Rajkarunanayake I., Wang J., Gentry L.E., Wang X.F., Brattain M.G. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem. 269:1994;26449-26455.
246. Kim I.Y., Ahn H.-J., Zelner D.J., Shaw J.W., Sensibar J.A., Kim J.H., Kato M., Lee C. Genetic change in transforming growth factor-β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res. 56:1996;44-48.
247. Ciernik I.F., Ciernik B., Cockerell C., Minna J., Gazdar A., Carbone D. Expression of transforming growth factor-β and transforming growth factor-β receptors on AIDS-associated Kaposi sarcoma. Clin. Cancer Res. 1:1995;1119-1124.
248. Riggins G.J., Thiagalingam S.E.R., Weinstein C.L., Kern S.E., Hamilton S.R., Willson J.K.V., Markowitz S.D., Kinzler K.W., Vogelstein B. Mad-related genes in the human. Nature Genet. 13:1996;347-349.
249. Thiagalingam S., Lengauer C., Leach F.S., Schutte M., Hahn S.A., Overhauser J., Willson J.K.V., Markowitz S., Hamilton S.R., Kern S.E., Kinzler K.W., Vogelstein B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genet. 13:1996;343-346.
250. Schutte M., Hiruban R.H., Hedrick L., Cho K., Molnar Nadasdy G., Weinstein C.L., Bova G.S., Isaacs W.B., Cairns P., Nawroz H., Sidransky D., Casero R.A., Meltzer P.S., Hahn S.A., Kern S.E. DPC4 gene in various tumor types. Cancer Res. 56:1996;2527-2530.
251. Kim S.K., Fan Y., Papadimitrakopulou V., Clayman G., Hittelman W.N., Hong W.K., Lotan R., Mao L. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous carcinoma. Cancer Res. 56:1996;2519-2521.
252. Nagatake M., Takagi Y., Osada H., Uchida K., Mitsudomi T., Saji S., Shimokata K., Takahashi T., Takahashi T. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 56:1996;2718-2720.
253. Uchida K., Nagatake M., Osada H., Yatabe Y., Kondo M., Mitsudomi T., Masuda A., Takahashi T., Takahashi T. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res. 56:1996;5583-5585.
254. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753-756.
255. Jen J., Harper J., Bigner S., Bigner D.D., Papadopoulos N., Markowitz S., Willson J.K., Kinzler K.W., Vogelstein B. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54:1994;6353-6358.
256. Zhang S., Endo S., Koga H., Ichikawa T., Feng X., Onda K., Washiyama K., Kumanishi T. A comparative study of glioma cell lines for p16, p15, p53 and p21 gene alterations. Japanese J. Cancer Res. 87:1996;900-907.
257. Akama Y., Yasui W., Kuniyasu H., Yokozaki H., Akagi M., Tahara H., Ishikawa T., Tahara E. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines. Japanese J. Cancer Res. 87:1996;824-830.
258. Kumanishi T., Zhang S., Ichikawa T., Endo S., Washiyama K. Primary malignant lymphoma of the brain: demonstration of frequent p16 and p15 gene deletions. Japanese J. Cancer Res. 87:1996;691-695.
259. Meltzer S.J. The molecular biology of esophageal carcinoma. Recent Results in Cancer Res. 142:1996;1-8.
260. Xiao S., Li D., Corson J.M., Vijg J., Fletcher J.A. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res. 55:1995;2968-2971.
261. Washimi O., Nagatake M., Osada H., Ueda R., Koshikawa T., Seki T., Takahashi T., Takahashi T. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res. 55:1995;514-517.
262. Naumann M., Savitskaia N., Eilert C., Schramm A., Kalthoff H., Schmiegel W. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology. 110:1996;1215-1224.
263. M. Zariwala, E. Liu, Y. Xiong, Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors, Oncogene (1996) 451-455.
264. Orlow I., Lacombe L., Hannon G.J., Serrano M., Pellicer I., Dalbagni G., Reuter V.E., Zhang Z.F., Beach D., Cordon-Cardo C. Deletion of the p16 and p15 genes in human bladder tumors. J. Natl. Cancer Inst. 87:1995;1524-1529.
265. Gombart A.F., Morosetti R., Miller C.W., Said J.W., Koeffler H.P. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. Blood. 86:1995;1534-1539.
266. Zhou X., Suzuki H., Shimada Y., Imamura M., Yin J., Jiang H.Y., Tarmin L., Abraham J.M., Meltzer S.J. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines. Genes, Chromosomes and Cancer. 13:1995;285-290.
267. Herma J.G., Jen J., Merlo A., Baylin S.B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56:1996;722-727.
268. Goretzki P.E., Gorelov V., Dotzenrath C., Witte J., Roeher H.D. A frequent mutation/polymorphism in tumor suppressor gene INK4B (MTS-2) in papillary and medullary thyroid cancer. Surgery. 120:1996;1081-1088.
269. Suzuki H., Zhou X., Yin J., Lei J., Jiang H.Y., Suzuki Y., Chan T., Hannon G.J., Mergner W.J., Abraham J.M.et al. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. Human Mol. Genet. 4:1995;1883-1887.
270. Li C.-Y., Suardet L., Little J. Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J. Biol. Chem. 270:1994;4971-4974.
271. Kip1, a cyclin-dependent kinase-inhibitor and a potential mediator of extracellular anti-mitogenic signals. Cell. 78:1994;59-66.
272. Kawamata N., Morosetti R., Miller C.W., Park D., Spirin K.S., Nakamaki T., Takeuchi S., Hatta Y., Simpson J., Wilcyznski S.et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55:1995;2266-2269.
273. Torre-Amione G., Beauchamp R.D., Koeppen H., Park B.H., Schreiber H., Moses H.L., Rowley D.A. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA. 87:1990;1486-1490.
274. Arrick B.A., Lopez A.R., Elfman F., Ebner R., Damsky C.H., Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor-β1. J. Cell. Biol. 118:1992;715-726.
275. Chang H.L., Gillet N., Figari I., Lopez A.R., Palladino M.A., Derynck R. Increased transforming growth factor β expression inhibits cell proliferation in vitro yet increases tumorigenicity and tumor growth of MethA sarcoma cells. Cancer Res. 53:1993;4391-4398.
276. Sieweke M.H., Thompson N.L., Sporn M.B., Bissell M.J. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-β Science. 248:1990;1656-1660.
277. Pierce D.F. Jr., Gorska A.E., Chytil A., Meise K.S., Page D.L., Coffey R.J. Jr., Moses H.L. Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc. Natl. Acad. Sci. USA. 92:1995;4254-4258.
278. Arteaga C.L., Coffey R.J. Jr., Dugger T.C., McCutchen C.M., Moses H.L., Lyons R.M. Growth stimulation of human breast cancer cells with anti-transforming growth factor-β antibodies: evidence for negative autocrine regulation by transforming growth factor-β Cell Growth Differ. 1:1990;367-374.
279. Wu S.P., Theodorescu D., Kerbel R.S., Willson J.K., Mulder K.M., Humphrey L.E., Brattain M.G. TGF-β1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J. Cell Biol. 116:1992;187-196.
280. Glick A.B., Kulkarni A.B., Tennenbaum T., Hennings H., Flanders K.C., O'Reilly M., Sporn M.B., Karlsson S., Yuspa S.H. Loss of expression of transforming growth factor-β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc. Natl. Acad. Sci. USA. 90:1993;6076-6080.
281. Glick A.B., Lee M.M., Darwiche N., Kulkarni A.B., Karlsson S., Yuspa S.H. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev. 8:1994;2429-2440.
282. Cui W., Fowlis D.J., Bryson S., Duffie E., Ireland H., Balmain A., Akhurst R. TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 86:1996;531-542.
283. Welch D.R., Fabra A., Nakajima M. Transforming growth factor-β1 stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Natl. Acad. Sci. USA. 87:1990;7678-7682.
284. Steiner M.S., Barrack E.R. Transforming growth factor-β1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol. Endocrinol. 6:1992;15-25.
285. Arteaga C.L., Carty-Dugger T., Moses H.L., Hurd S.D., Pietenpol J.A. Transforming growth factor-β1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ. 4:1993;193-201.
286. Cheng K.C., Loeb L.A. Genomic instability and tumor progression: mechanistic considerations. Adv. Cancer Res. 60:1993;121-156.